Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
McKesson
Julphar
Moodys
Cipla
AstraZeneca
Harvard Business School
UBS
Cerilliant
Colorcon

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Retroviral protease inhibiting compounds
Abstract:A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
Inventor(s): Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing L. (Gurnee, IL), Zhao; Chen (Gurnee, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Filing Date:Apr 04, 1995
Application Number:08/416,272
Claims:1. A compound of the formula: ##STR18## wherein R.sub.1 is monosubstituted isoxazolyl or monosubstituted isothiazolyl wherein the substituent is selected from (i) heterocyclic wherein the heterocyclic is selected from aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl and pyrazinyl and wherein the heterocyclic is unsubstituted or substituted with a substituent selected from halo, C.sub.1 -to-C.sub.6 -loweralkyl, hydroxy, C.sub.1 -C.sub.6 -alkoxy or benzyloxy and C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S-- and (ii) (heterocyclic)-C.sub.1 -to-C.sub.6 -alkyl wherein heterocyclic is defined as above;

n is 1, 2 or 3;

R.sub.2 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl;

R.sub.3 is C.sub.1 -to-C.sub.6 -loweralkyl;

R.sub.4 and R.sub.4a are independently selected from phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from (i) halo, (ii) C.sub.1 -to-C.sub.6 -loweralkyl, (iii) hydroxy, (iv) C.sub.1 -to-C.sub.6 -alkoxy or benzyloxy and (v) C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S--;

R.sub.6 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl;

R.sub.7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted or substituted with C.sub.1 -to-C.sub.6 -loweralkyl;

X is hydrogen and Y is --OH; and

Z is absent, --O--, --S--, --CH.sub.2 -- or --N(R.sub.8)-- wherein R.sub.8 is C.sub.1 -to-C.sub.6 -loweralkyl, C.sub.3 -to C.sub.7 -cycloalkyl, --OH or --NHR.sub.8a wherein R.sub.8a is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl; or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 wherein n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen and R.sub.7 is thiazolyl or oxazolyl.

3. The compound of claim 1 n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen and R.sub.7 is 5-thiazolyl or 5-oxazolyl.

4. The compound of claim 1 wherein n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --O-- or --N(R.sub.8)-- wherein R.sub.8 is C.sub.1 -to-C.sub.6 -loweralkyl.

5. The compound of claim 1 wherein n is 1; R.sub.2 is hydrogen; R.sub.3 is methyl or isopropyl; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --O--.

6. The compound of claim 1 wherein n is 1; R.sub.2 is hydrogen; R.sub.3 is isopropyl; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --N(R.sub.8)-- wherein R.sub.8 is methyl.

7. A compound of the formula: ##STR19## wherein R.sub.1 is monosubstituted isoxazolyl or monosubstituted isothiazolyl wherein the substituent is selected from (i) heterocyclic wherein the heterocyclic is selected from aziridinyl, aziridinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyridazinyl and pyrazinyl and wherein the heterocyclic is unsubstituted or substituted with a substituent selected from halo, C.sub.1 -to-C.sub.6 -loweralkyl, hydroxy, C.sub.1 -to-C.sub.6 -alkoxy or benzyloxy and C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S-- and (ii) (heterocyclic)-C.sub.1 -to-C.sub.6 -alkyl wherein heterocyclic is defined as above;

n is 1, 2 or 3;

R.sub.2 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl;

R.sub.4 and R.sub.4a are independently selected from phenyl wherein the phenyl ring is unsubstituted or substituted with a substituent selected from (i) halo, (ii) C.sub.1 -to-C.sub.6 -loweralkyl, (iii) hydroxy, (iv) C.sub.1 -to-C.sub.6 -alkoxy or benzyloxy and (v) C.sub.1 -to-C.sub.6 -thioalkoxy or benzyl-S--;

R.sub.6 is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl;

R.sub.7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is unsubstituted and R.sub.3 is C.sub.2 - to-C.sub.6 - loweralkyl and Z is absent, --O--, --S-- or --CH.sub.2 --;

or

R.sub.7 is thiazolyl or oxazolyl wherein the thiazolyl or oxazolyl ring is substituted with C.sub.1 -to-C.sub.6 -loweralkyl and R.sub.3 is C.sub.1 -to-C.sub.6 -loweralkyl and Z is absent, --O--, --S--, --CH.sub.2 -- or --N(R.sub.8)-- wherein R.sub.8 is C.sub.1 - to-C.sub.6 -loweralkyl, C.sub.3 -to-C.sub.7 -cycloalkyl, --OH or --NHR.sub.8 a wherein R.sub.8a is hydrogen or C.sub.1 -to-C.sub.6 -loweralkyl; and

X is --OH and Y is hydrogen;

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 7 wherein n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen and R.sub.7 is thiazolyl or oxazolyl.

9. The compound of claim 7 wherein n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen and R.sub.7 is 5-thiazolyl or 5-oxazolyl.

10. The compound of claim 7 wherein n is 1; R.sub.2 is hydrogen; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --O--.

11. The compound of claim 7 wherein n is 1; R.sub.2 is hydrogen; R.sub.3 is methyl or isopropyl; R.sub.4 is phenyl; R.sub.5 is hydrogen; R.sub.6 is hydrogen; R.sub.7 is 5-thiazolyl or 5-oxazolyl; and Z is --O--.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Merck
Farmers Insurance
Cantor Fitzgerald
Fish and Richardson
Boehringer Ingelheim
AstraZeneca
Teva
McKinsey
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot